Godavari Drugs Ltd — Board Meeting, 13-08-2025: Board Meeting

Godavari Drugs has approved the financial results for the quarter ended June 30, 2025, reporting revenue from operations of ₹23.81 Cr and a net profit of ₹1.04 Cr. In a strategic move, the company proposes to increase its Authorised Share Capital from ₹10 Cr to ₹20 Cr, pending shareholder approval. This expansion of capital base could facilitate future growth initiatives or funding needs. Additionally, the 37th Annual General Meeting has been rescheduled to September 27, 2025, for operational and compliance reasons.